ReviewNature plants2026
Advancing the adoption of RNA interference-based biopesticides.
Review in Nature plants, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA interference (RNAi)-based biopesticides use a natural cellular mechanism to specifically silence genes essential for pest or pathogen fitness, offering a targeted and potentially safer alternative to conventional chemical sprays. The recent registration of the first products targeting Colorado potato beetle and varroa mite marks the transition of this technology from proof of concept to practical reality. With technical feasibility established, attention is shifting to the drivers determining adoption into pest management strategies. The potential for uptake by farmers can be framed within a decision-making process that weighs the choice to deploy this new tool against a backdrop of environmental concerns, widespread pesticide resistance and increasing regulatory restrictions related to conventional synthetic chemistries. Shifting dynamics have influenced the return-on-investment proposition, where agricultural utility (safe and reliable efficacy against pests and pathogens), regulatory reality (barriers to availability) and social licence (public perception and acceptance of novel biotechnologies) act as the levers shifting the cost-benefit ratio of RNAi-based biopesticides relative to conventional options. Advancements in bioinformatics-driven double-stranded RNA design, risk assessment and delivery systems position RNAi-based biopesticides as an alternative to fill the market gap created by the withdrawal of conventional chemistries. However, widespread adoption must navigate fragmented international regulatory harmonization and the challenges of developing a social licence to operate, specifically regarding public perceptions of safety, residues and the use of novel biotechnology tools.
Identifiers
42744871What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.